- Home
- PTIX vs PRFX Comparison
PTIX vs PRFX Comparison
Compare PTIX & PRFX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PTIX
- PRFX
- Stock Information
- Founded
- PTIX 1994
- PRFX 2007
- Country
- PTIX United States
- PRFX Israel
- Employees
- PTIX N/A
- PRFX N/A
- Industry
- PTIX Biotechnology: Pharmaceutical Preparations
- PRFX Biotechnology: Pharmaceutical Preparations
- Sector
- PTIX Health Care
- PRFX Health Care
- Exchange
- PTIX Nasdaq
- PRFX Nasdaq
- Market Cap
- PTIX 2.7M
- PRFX 2.8M
- IPO Year
- PTIX 2016
- PRFX 2020
- Fundamental
- Price
- PTIX $3.25
- PRFX $1.40
- Analyst Decision
- PTIX
- PRFX Hold
- Analyst Count
- PTIX 0
- PRFX 1
- Target Price
- PTIX N/A
- PRFX N/A
- AVG Volume (30 Days)
- PTIX 8.3M
- PRFX 8.8M
- Earning Date
- PTIX 09-10-2025
- PRFX 09-23-2025
- Dividend Yield
- PTIX N/A
- PRFX N/A
- EPS Growth
- PTIX N/A
- PRFX N/A
- EPS
- PTIX N/A
- PRFX N/A
- Revenue
- PTIX N/A
- PRFX N/A
- Revenue This Year
- PTIX N/A
- PRFX N/A
- Revenue Next Year
- PTIX N/A
- PRFX N/A
- P/E Ratio
- PTIX N/A
- PRFX N/A
- Revenue Growth
- PTIX N/A
- PRFX N/A
- 52 Week Low
- PTIX $2.25
- PRFX $1.25
- 52 Week High
- PTIX $15.54
- PRFX $16.63
- Technical
- Relative Strength Index (RSI)
- PTIX 49.71
- PRFX 46.40
- Support Level
- PTIX $2.79
- PRFX $1.32
- Resistance Level
- PTIX $3.39
- PRFX $1.47
- Average True Range (ATR)
- PTIX 0.35
- PRFX 0.13
- MACD
- PTIX -0.04
- PRFX -0.02
- Stochastic Oscillator
- PTIX 20.42
- PRFX 11.67
About PTIX Protagenic Therapeutics Inc.
Protagenic Therapeutics Inc is a biopharmaceutical company focused on the discovery and development of therapeutics to treat stress-related neuropsychiatric and mood disorders. It provides treatments for mood, anxiety, depression, and neurodegenerative disorders by using peptide-based and brain-active therapeutics. The company's main compound, PT00114, is a synthetic form of Teneurin Carboxy-terminal Associated Peptide, an endogenous brain signaling peptide that can dampen overactive stress responses. It has also created a portfolio of novel neuropeptides that are in various stages of development and preclinical evaluation for the treatment of mood disorders.
About PRFX PainReform Ltd.
PainReform Ltd is a clinical-stage specialty pharmaceutical company. It is focused on the reformulation of established therapeutics. The company's product PRF-110 is based on the local anesthetic ropivacaine, targeting the post-operative pain relief market. PRF-110 is an oil-based, viscous, clear solution that is deposited directly into the surgical wound bed before closure to provide localized and extended post-operative analgesia.